Charles River Laboratories International (NYSE:CRL) Releases FY 2026 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 11.450-11.450 for the period, compared to the consensus earnings per share estimate of 11.330. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Charles River Laboratories International Price Performance

NYSE CRL opened at $277.44 on Thursday. The company has a 50-day moving average price of $267.76 and a two-hundred day moving average price of $211.63. The stock has a market cap of $13.24 billion, a price-to-earnings ratio of -57.20, a price-to-earnings-growth ratio of 2.80 and a beta of 1.40. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. Charles River Laboratories International has a 52 week low of $144.26 and a 52 week high of $303.30.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. During the same period last year, the firm posted $3.12 earnings per share. The business’s revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts forecast that Charles River Laboratories International will post 11.33 EPS for the current year.

Wall Street Analyst Weigh In

CRL has been the subject of a number of research reports. Barclays reaffirmed an “overweight” rating and set a $300.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a report on Wednesday, July 1st. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a research note on Monday, August 10th. Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Finally, BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Eleven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and an average price target of $273.81.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Victoria Creamer sold 4,179 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the transaction, the executive vice president directly owned 30,051 shares of the company’s stock, valued at $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Nancy C. Andrews sold 573 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the sale, the director directly owned 1,438 shares of the company’s stock, valued at $410,175.12. The trade was a 28.49% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 165,990 shares of company stock worth $42,606,388. 1.30% of the stock is currently owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.